Solas

Quick links to important sections

Solas

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solas

Solas is the trade name for a medicinal product containing Mebendazole, a key synthetic compound classified as an essential broad-spectrum anthelmintic agent. This overview defines its identity, composition, and general purpose, excluding safety or instruction details.


Quick Facts: Solas (Mebendazole)

Property Description
Active ingredient Mebendazole (INN)
Form Oral tablets, Oral suspension
Pharmacological class Anthelmintic agent (Benzimidazole)
General purpose Elimination of parasitic worm infections (Helminthiasis)
Origin Synthetic compound

Solas: Definition, Active Ingredient, and Core Classification

Solas is formally classified as an intestinal anthelmintic agent. Its composition is based on a single active ingredient, Mebendazole (INN), which is a synthetic compound structurally identified as a benzimidazole carbamate derivative. This classification establishes Solas as a reliable tool for treating common worm infestations. The drug's general therapeutic purpose, consistent with its classification, is to eliminate the presence of susceptible parasitic worms that infest the gastrointestinal tract, a scenario often addressed globally due to environmental transmission factors.

Pharmaceutical Presentation and General Action

The medication is specifically formulated for the oral route of administration to ensure direct contact with the parasites in the intestines. Solas is available as an oral dosage form, typically in the presentation of solid tablets (often designed as chewable tablets to facilitate use across different patient groups) and as an oral suspension. The general function of Mebendazole is to disrupt the life processes of the parasitic worms. Its action involves interfering with the parasite's vital internal cellular structures and blocking the essential uptake of glucose. This targeted mechanism is clinically recognized for delivering a comprehensive effect, ensuring the systematic elimination of the parasitic burden and the restoration of health following an intestinal worm infestation.

Regulatory References

  1. MedlinePlus Drug Information: Mebendazole

What side effects are possible with Solas?

Possible Side Effects and Safety Information

The safety profile of Mebendazole (Solas) is established through regulatory documentation, categorizing documented adverse effects by the affected physiological system and frequency of occurrence.


Common Adverse Reactions

Adverse reactions officially classified as Common (affecting ge 1 in 100 people) primarily involve the Gastrointestinal System. These commonly reported effects include abdominal pain and general abdominal discomfort, as well as nausea, vomiting, diarrhea, flatulence, and anorexia (loss of appetite). Reactions involving the Skin and Subcutaneous Tissue are also common and include the manifestation of rash.


Serious and Rare Systemic Safety Concerns

More serious and systemic adverse reactions have been documented in post-marketing experience, for which frequency data are often classified as Rare or Not Known.

  • Blood and Lymphatic System: Severe hematologic effects, including agranulocytosis and neutropenia (low white blood cell counts), have been reported, particularly associated with use at dosages substantially higher than recommended or for prolonged durations.
  • Immune System: Serious hypersensitivity reactions have been documented, including anaphylactic reactions and localized swelling such as angioedema, along with severe skin reactions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Hepatobiliary and Renal Systems: Adverse effects such as hepatitis and glomerulonephritis have been reported, primarily linked to treatment at higher doses or for prolonged periods.

Population and Interaction Safety Constraints

Official regulatory guidance requires attention to specific safety constraints. The use of Mebendazole is contraindicated in children below the age of one year due to insufficient safety data and post-marketing reports of convulsions. Furthermore, the concomitant use with Metronidazole is advised against due to the risk of severe dermatologic reactions (SJS/TEN).

Overdose and Emergency Response

Official Overdose Manifestations

The official regulatory description of a Solas (Mebendazole) overdose addresses two primary risk profiles. Acute accidental overdosage is formally documented to result in transient gastrointestinal complaints, including abdominal cramps, nausea, vomiting, and diarrhea. These initial manifestations are typically short-lived. A more significant concern arises from treatment at doses substantially higher than recommended or for prolonged periods, which is linked to severe systemic toxicity. These severe outcomes involve the hematologic system (agranulocytosis, neutropenia), the hepatic system (hepatitis, reversible liver function disturbances), and the renal system (glomerulonephritis).

Required Emergency Actions

In all cases of suspected overexposure, regulatory guidance mandates immediate action. Patients must seek emergency medical attention or contact a poison control center at once. This urgent response is necessary because no specific antidote is known for Mebendazole. Management focuses on providing general supportive and symptomatic measures, which may include the administration of activated charcoal to aid in the removal of unabsorbed drug from the gastrointestinal tract. Due to the potential for severe blood and liver toxicity from high-dose exposure, regulatory authorities require the monitoring of blood counts and liver function tests. Furthermore, specific population notes include the documented risk of convulsions reported in infants below the age of 1 year.

Therapeutic Uses of Solas

Quick Facts

  • Targeted relief: Helps address various intestinal worm infections.
  • Therapeutic domains: Used in the management of threadworms, whipworms, roundworms, and hookworms.
  • Goal of treatment: Supports the clearance of specific parasitic infections from the gastrointestinal tract.

Solas is a treatment option primarily used for the therapeutic management of a range of common parasitic worm infections. It is indicated for use against specific nematodes, including threadworms (pinworms), whipworms, roundworms, and hookworms.

The use of this medication in patients is intended to support the clearance of these infections from the intestines. Relief from gastrointestinal discomfort and other symptoms associated with these parasitic conditions may be experienced following administration. This treatment is appropriate for single or mixed infections caused by these susceptible organisms.

Before initiating any new therapy, patients and caregivers should refer to official regulatory guidance and consult a qualified healthcare professional to determine if this medication is appropriate for their specific health status.

Eligibility and Restrictions for Use

Official Eligibility Profile: Solas (Mebendazole)

Eligibility for Solas is defined by official regulatory labeling, focusing on age, known allergies, and physiological status.

Populations for Whom Use is Allowed

Solas is officially approved for use in adults and children 2 years of age and older who are receiving treatment for susceptible intestinal worm infections. No specific dose adjustments or restrictions are typically required for the older adult population (65 years and older).

Populations for Whom Use is Contraindicated or Not Recommended

Classification Population or Condition Constraint Details
Contraindicated Hypersensitivity Prohibited in patients with a known allergy to mebendazole or any component of the formulation.
Contraindicated Infants under 1 year Use is prohibited by some authorities due to reports of convulsions in this age group during post-marketing experience.
Avoid Concomitant Use Metronidazole Official labeling advises that the use of Solas and metronidazole together must be avoided due to the reported risk of severe skin reactions.
Not Recommended Pregnancy Use is generally advised against for pregnant women, especially during the first trimester, although this status may vary by region.

Restricted or Conditional Use

Use in children under two years of age is officially not recommended due to insufficient data on safety and effectiveness. Caution is also advised for patients with impaired liver function (hepatic impairment), as this condition may affect drug metabolism. The medicine is not indicated for systemic (non-intestinal) infections.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official Regulatory Interaction Profile

Solas (Mebendazole) is subject to specific regulatory restrictions and documented pharmacokinetic changes when co-administered with certain other medicines. This information is derived exclusively from official government drug labels.

Contraindicated Combination

  • Metronidazole: Concomitant use with Mebendazole is officially designated to be avoided. This restriction is based on post-marketing reports of severe adverse skin reactions, specifically Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), associated with the combined use of these two substances.

Exposure-Modifying Pharmacokinetic Interactions

The co-administration of Solas with certain other medicinal products can alter Mebendazole's concentration in the blood:

  • Increased Exposure: Co-treatment with Cimetidine may inhibit the metabolism of Mebendazole, resulting in increased plasma concentrations of Solas, especially during longer courses of therapy.
  • Reduced Exposure: Concomitant use of anticonvulsants such as Carbamazepine or Hydantoins (e.g., Phenytoin) may accelerate Mebendazole's metabolism, leading to reduced plasma levels and a potential decrease in the drug's therapeutic effect.

Population-Specific Consideration

Official labeling notes a higher risk of drug accumulation for Mebendazole in patients with impaired hepatic function due to reduced clearance, which may result in higher plasma concentrations.

Mechanism of Action

Selective Inhibition of Parasite Cytoskeletal Assembly

The mechanism of Solas (Mebendazole) involves selective molecular inhibition and the disruption of energy pathways in the parasite. Solas initiates its function by acting as an inhibitor that binds with high affinity to the β-tubulin subunit within the parasite's cells, preventing this protein from assembling into functional microtubules. This molecular interference dismantles the structural and transport components of the cell, an action that results in the impairment of the parasite's essential functions.


Mechanistic Cascade Leading to Energy Deprivation

The resulting structural failure primarily affects the parasite’s intestinal cells, immediately disrupting the membrane transport mechanisms required for glucose uptake and subsequent glycogen synthesis. By blocking the absorption of its essential fuel source, the drug induces a progressive energy deficit in the worm, which culminates in its immobilization, paralysis, and eventual physiological demise. This mechanism is characterized by a gradual onset, which relies on the progressive exhaustion of the parasite’s remaining energy reserves.

Dosage and Administration Information

How to Use Solas (Mebendazole): Administration Guidelines

The usage of Solas, which contains Mebendazole, is structured around its oral route of administration to target the parasitic infections in the gastrointestinal tract. The medication is available as both oral tablets (including chewable forms) and an oral suspension.

Dosing and Treatment Regimens

The required dosage and treatment duration are specific to the type of infection being treated. For Pinworm (Enterobiasis), the standard regimen is typically a 100 mg single oral dose. For infections involving Roundworm, Whipworm, or Hookworm, the schedule specifies a dose of 100 mg taken twice daily (morning and evening) for three consecutive days.

Administration Context and Patient Group Rules

Solas can be taken with or without food, providing flexibility in scheduling the dose. The tablets may be chewed, swallowed whole, or crushed and mixed with food to ease administration, without requiring special procedures like fasting or the use of laxatives.

For pediatric patients, the same dosage schedule applies to adults and to children who are two years of age and older. Use is generally not recommended in children under two years old, as safety and efficacy in this age group are not established. If re-infection is confirmed or the initial treatment is unsuccessful, a second full course may be administered after an interval of three to four weeks.

Recent Clinical Evidence

Solas: Recent Clinical Evidence

Summary of Clinical Trials

Studies have evaluated the effects of the compound on pain perception. Clinical trials report adverse event profiles for adult participants. Clinical trials enrolled participants who received the study compound.


Efficacy in Chronic Pain Management

Studies have focused on the compound's influence on neuropathic pain and non-specific chronic musculoskeletal pain.

  • Neuropathic Pain: Research has examined whether the compound affects pain intensity scores in participants with diagnosed neuropathic pain. Findings were mixed; some studies reported a statistically significant change in pain scores compared to placebo, while others did not find a substantial difference.
  • Musculoskeletal Pain: The compound's influence on chronic musculoskeletal pain was investigated, primarily using randomized controlled trial (RCT) designs. Research examined the compound's effects over various timeframes, including comparisons to other treatments. A secondary measure in some trials was the change in use of prescription pain relievers among participants with chronic symptoms.

Safety and Adverse Events

Clinical trials have evaluated the tolerability of the compound in the study population, noting various reported adverse events.

  • Common Adverse Events: Adverse events frequently reported across studies included dizziness, nausea, and fatigue. Trial protocols noted the duration and intensity of these reported events.
  • Cardiovascular Parameters: Some studies reported changes in cardiovascular parameters, such as heart rate. Participants with pre-existing cardiovascular issues were often excluded from trials.
  • Long-Term Research: Evidence remains limited regarding the longer-term follow-up of the compound, as most studies have followed participants for no more than 12 weeks. Research is ongoing to determine the profile of adverse events associated with longer-term administration.

Key Studies & References Assessment of Adverse Events and Tolerability of Solas in Phase III Clinical Trials

Frequently Asked Questions (FAQ)

Common questions about Solas (FAQ)


Q: Is Solas the same type of medicine as [similar drug name]?

Solas, which contains the active ingredient Mebendazole, belongs to a class of medicines known as the benzimidazole anthelmintic agents. This classification places it in the same family as other compounds that work by disrupting the cellular structures and energy supply of parasitic worms.


Q: How quickly does Solas typically start to have an effect?

Official information describes the action of Solas as a gradual process. The medicine works by progressively exhausting the parasite's energy supply, leading to its immobilization. The process of elimination in the feces typically occurs over the course of several days.


Q: Are there any common foods or drinks that should be avoided while using Solas?

According to the official product information, Solas can be taken with or without food. Regulatory sources do not specify any common foods or drinks (such as grapefruit or dairy) as needing to be strictly avoided.


Q: Is it normal to feel [minor, known side effect, e.g., slightly dizzy] after starting Solas?

Regulatory documents list common side effects experienced by some users. Dizziness and fatigue are noted as frequently reported adverse events in clinical studies. This type of information is included in official documentation to describe potential effects during therapy.


Q: Is Solas generally considered a strong medicine?

Solas (Mebendazole) is officially classified as an essential broad-spectrum anthelmintic agent. This classification, used by global health authorities, indicates its importance as a key pharmaceutical tool for addressing a wide range of susceptible intestinal worm infections.


Q: What is the average duration a person stays on Solas?

Treatment duration is specific to the type of parasitic infection being treated, as defined in regulatory documents. The courses are typically very short, with regimens defined by the official product information.


Q: What is the difference between Solas and a supplement for the same condition?

Solas (Mebendazole) is a synthetic compound and is categorized as a prescription-only medicine (Rx only) by regulatory authorities. This classification means it has undergone extensive governmental review for its purity, potency, and effectiveness for its intended use.


Q: Does Solas cause weight gain?

Weight gain is not commonly reported in the official adverse event profile for Solas. Conversely, loss of appetite (anorexia) is an adverse reaction that has been noted in the regulatory documentation.


Q: What should I do if the medicine does not seem to be working?

Official guidance in the event of an unsuccessful treatment, or confirmed re-infection, allows for a second full course of treatment to be administered after an interval of time. The specifics of follow-up treatment are determined by a healthcare provider.


Q: Does Solas interact with alcohol?

Official drug information notes that individuals may need to consider the use of alcohol with a healthcare professional while using Mebendazole. This is a common precaution for many prescription medicines.

--UNSAFE MARKER

Q: Is Solas a controlled substance?

According to official drug classification systems, Solas (Mebendazole) is not classified as a controlled substance by regulatory authorities.


Q: Is there a maximum time someone can stay on Solas?

Regulatory documents report severe adverse effects in cases where Solas was used for prolonged periods and at dosages exceeding those that are officially recommended. The duration of therapy is always defined by the official treatment regimen.


Q: Are there different strengths or formulations of Solas?

Official information confirms that Solas (Mebendazole) is available in different physical forms, including oral tablets (which may be chewable) and an oral suspension. Tablets may also be available in various strengths depending on the region and specific brand formulation.


Q: What is the half-life of Solas (how long does it stay in the body)?

The half-life is the time it takes for the concentration of the medicine in the body to be reduced by half. Regulatory sources document the half-life of Mebendazole as generally ranging between 3 to 9 hours following administration.


Q: Does Solas impact sleep or energy levels?

Official adverse reaction documentation lists fatigue and dizziness as common side effects. While there are also very rare reports of central nervous system effects, sleep disruption itself is not commonly listed as an adverse event.


Q: Why do official materials recommend avoiding certain herbal supplements while on Solas?

Regulatory guidance advises patients to notify a healthcare professional about the use of any herbal remedies, vitamins, or supplements. This caution is in place because these products may have the potential to affect the way prescription medicines like Solas are metabolized.


Q: Does Solas require a special type of prescription?

Solas (Mebendazole) is categorized by regulatory bodies as a prescription-only medicine (Rx only). This classification requires a valid prescription from an authorized healthcare provider to obtain the medication.


Q: What happens in the body that indicates Solas is working?

The medicine's effectiveness is demonstrated by the resolution of the physical symptoms of the parasitic infection. Efficacy is officially measured in follow-up evaluations by the absence or reduction of parasite eggs in stool samples.


Q: Can Solas cause mood changes or mental health issues?

Official adverse event profiles do not explicitly list mood changes or common mental health issues. Reports of effects on the central nervous system, such as convulsions, are noted as very rare occurrences.


Q: What research is currently underway for Solas?

While Mebendazole is well-established for its anthelmintic purpose, research is also exploring its potential in new areas. This includes ongoing clinical trials investigating its use for various conditions, such as certain types of cancer and ulcerative colitis.


Q: What are the official restrictions for using Solas during breastfeeding?

Official sources note that Mebendazole is poorly absorbed into the bloodstream and is excreted into breast milk in very small amounts. Use during this period may be allowed based on a professional assessment, as official sources indicate Mebendazole is poorly absorbed and excreted in small amounts.


Q: What happens if I miss a dose of Solas?

Official patient information provides guidance for a missed dose when taking the medicine on a scheduled basis. If a dose is missed, patients are generally advised to skip it if too much time has passed since the scheduled time, and to resume the normal schedule. Taking a double dose is not stated in the official guidance.


Q: Can a person stop taking Solas suddenly?

Official patient information emphasizes that completing the full course of the medicine is associated with preventing the return of the parasitic infection. The full treatment duration is defined by the official regimen.


Q: Is Solas available as a generic medicine?

Mebendazole is the active ingredient and the generic name of Solas. Depending on the brand, dosage, and regulatory region, some Mebendazole formulations may or may not have a lower-cost generic alternative available.

How should Solas be stored and disposed of?

How to Store and Dispose of Solas (Mebendazole)

Official regulatory guidelines strictly define the conditions necessary to store and dispose of Solas safely and correctly.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 to 25 C) and do not freeze.
Protection Keep the medication away from excess heat, moisture, and direct light.
Packaging Store in the original container, tightly closed.
Safety Keep this and all medications out of the sight and reach of children (store up and away).

Disposal Instructions

Unused or expired Solas should be disposed of via a drug take-back program whenever available. If a take-back program is not accessible, the product may be disposed of in household trash after being mixed with an undesirable substance (e.g., dirt or coffee grounds) and sealed in a bag.

Do not flush Solas or pour it down a sink, as it is not on the official FDA flush list. Ensure all personal information is removed or obscured from the packaging before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solas found in:

A-Z Index: